Confusion between approved injectable epinephrine products and unapproved nasal solutions has prompted a warning to ...

ARS Pharmaceuticals launched Neffy, the first FDA-approved needle-free epinephrine nasal spray for severe allergic reactions.

Please provide your email address to receive an email when new articles are posted on . The FDA has advised health care professionals that they should not use unapproved epinephrine nasal ...

ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to ...

Epinephrine nasal solutions from BPI Labs and Endo USA should not be used, according to the FDA. Similarities between the packaging for certain intranasal and intravenous epinephrine products may ...

neffyinSchools provides eligible public and private K-12 schools in the U.S. with the opportunity to receive two cartons (four single use doses) of neffy ® (epinephrine nasal spray) 2 mg for use ...

School administrators and nurses are encouraged to review applicable state laws and regulations to ensure neffy ® (epinephrine nasal spray) 2 mg for undesignated use meets applicable state law ...

(Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced ...

INDICATION AND IMPORTANT SAFETY INFORMATION FOR neffy (epinephrine nasal spray) INDICATIONneffy 2 mg is indicated for emergency treatment of Type I allergic reactions, including anaphylaxis ...

unaudited neffy ® (epinephrine nasal spray) net product revenue for the fourth quarter and full year 2024 and outlined its 2025 commercial and clinical objectives. Cash position: Cash ...

Absorption of neffy may be affected by underlying structural or anatomical nasal conditions. Administer with caution to patients who have heart disease; epinephrine may aggravate angina pectoris ...